No Data
No Data
Boji Medical Technology (300404.SZ): Received the notice of approval for clinical drug trials.
On December 24, Gelonghui reported that Boji Medical Technology (300404.SZ) announced that the "TBA Tablets" developed in collaboration with Guangdong Gumai Di Health Technology Co., Ltd. has received the "Notice of Approval for Clinical Drug Trials" issued by the National Medical Products Administration. TBA is a new, structurally defined compound with pharmacological effects and clinical value. It is a first-class Innovative Drug that has not been marketed domestically or internationally, with a proposed indication for drug-resistant pulmonary tuberculosis. Tuberculosis is a chronic and deadly infectious disease that is transmitted globally, primarily caused by Mycobacterium tuberculosis. TBA acts on the electron transport of mycobacteria.
Boji Medical TechnologyLtd's (SZSE:300404) 7.0% YoY Earnings Expansion Surpassed the Shareholder Returns Over the Past Five Years
Is Boji Medical Technology Co.,Ltd.'s (SZSE:300404) Recent Stock Performance Influenced By Its Fundamentals In Any Way?
Boji Medical Technology (300404.SZ): has been identified as a national level specialized, special and new "little giant" enterprise.
Gelonghui November 4th | Boji Medical Technology (300404.SZ) announced that recently, Boji Medical Technology Co., Ltd. received the specialized, special and new "Little Giant" enterprise certificate issued by the Ministry of Industry and Information Technology. The validity period of this specialized, special and new "Little Giant" enterprise is 3 years (July 1, 2024 - June 30, 2027).
Boji Medical Technology (300404.SZ) shareholders Zhao Lingli and Fermi No. 13 completed shareholding, totaling a 1.5% reduction in shares.
boji medical technology (300404.SZ) announced that the company has received the unanimous consent of the controlling shareholder and actual controller, Mr. Wang Tingchun...
boji medical technology (300404.SZ): Currently, the company has no research projects on anti-aging drugs.
According to Gelonhui on October 31, boji medical technology (300404.SZ) stated on the investor interaction platform that the company currently has no research projects on anti-aging drugs.
No Data